Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
Journal of Clinical Microbiology, Volume 59, No. 1, Article e02204-20, Year 2021
Notification
URL copied to clipboard!
Description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed over 1 million people. Informed implementation of government public health policies depends on accurate data on SARS-CoV-2 immunity at a population scale. We hypothesized that detection of SARS-CoV-2 salivary antibodies could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infection and seropositivity at a population scale. We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology that comprised 12 CoV antigens, mostly derived from SARS-CoV-2 nucleocapsid (N) and spike (S). Saliva and sera collected from confirmed coronavirus disease 2019 (COVID-19) cases and from the pre-COVID-19 era were tested for IgG, IgA, and IgM to the antigen panel. Matched saliva and serum IgG responses (n = 28) were significantly correlated. The salivary anti-N IgG response resulted in the highest sensitivity (100%), exhibiting a positive response in 24/24 reverse transcription-PCR (RT-PCR)-confirmed COVID-19 cases sampled at >14 days post-symptom onset (DPSO), whereas the salivary anti-receptor binding domain (RBD) IgG response yielded 100% specificity. Temporal kinetics of IgG in saliva were consistent with those observed in blood and indicated that most individuals seroconvert at around 10 DPSO. Algorithms employing a combination of the IgG responses to N and S antigens result in high diagnostic accuracy (100%) by as early as 10 DPSO. These results support the use of saliva-based antibody testing as a noninvasive and scalable alternative to blood-based antibody testing. Copyright © 2020 American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Pisanic, Nora
United States, Baltimore
Johns Hopkins University
Manabe, Yukari C.
United States, Baltimore
Johns Hopkins University
Thomas, David L.
United States, Baltimore
Johns Hopkins University
Pekosz, Andrew S.
United States, Baltimore
Johns Hopkins University
Klein, Sabra L.
United States, Baltimore
Johns Hopkins University
Betenbaugh, Michael James
United States, Baltimore
Johns Hopkins University
Clarke, William A.
United States, Baltimore
Johns Hopkins University
Laeyendecker, Oliver B.
United States, Baltimore
Johns Hopkins University
United States, Bethesda
National Institutes of Health Nih
Caturegli, Patrizio P.
United States, Baltimore
Johns Hopkins University
Larman, Harry Benjamin
United States, Baltimore
Johns Hopkins University
Detrick, Barbara
United States, Baltimore
Johns Hopkins University
Fairley, Jessica Kathleen
United States, Atlanta
Emory University
Sherman, Amy Caryn
United States, Atlanta
Emory University
Rouphael, Nadine G.
United States, Atlanta
Emory University
Edupuganti, Srilatha
United States, Atlanta
Emory University
Collins, Matthew H.
United States, Atlanta
Emory University
Statistics
Citations: 131
Authors: 16
Affiliations: 4
Identifiers
Doi:
10.1128/JCM.02204-20
ISSN:
00951137
Research Areas
Covid
Study Design
Cross Sectional Study